Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Henry Emerle

Psychiatry Davenport, IA Medical Doctor

NPI 1336450790 CMS profile 458532

1441 W Central Park Ave, Davenport, IA 52804

Open in the dashboard

General payments

$3,299

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Henry Emerle of Davenport, IA is reported in the CMS Open Payments database as having received $3,299 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,197 24
2024 General $562 10
2023 General $51 3
2022 General $28 2
2021 General $90 3
2020 General $33 3
2019 General $336 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Henry Emerle
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Henry Emerle were reported at $2,197. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Henry Emerle Psychiatry median Middle half National median
2019 $336 $184 $59–$605 $163
2020 $33 $119 $36–$372 $114
2021 $90 $143 $43–$576 $132
2022 $28 $153 $50–$590 $149
2023 $51 $170 $56–$651 $160
2024 $562 $179 $57–$673 $164
2025 $2,197 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $1,983 14 payments
  2. Neuronetics, Inc. $513 8 payments
  3. Allergan Inc. $177 26 payments
  4. Teva Pharmaceuticals USA, Inc. $144 3 payments
  5. ITI, Inc. $116 4 payments
  6. Otsuka America Pharmaceutical, Inc. $101 5 payments
  7. AbbVie, Inc. $84 4 payments
  8. Idorsia Pharmaceuticals US Inc $35 2 payments
  9. Alkermes, Inc. $30 2 payments
  10. Axsome Therapeutics, Inc. $19 1 payment
  11. Other $97 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,840 1 payment
  2. Food and Beverage $1,307 72 payments
  3. Education $151 2 payments
Products named General payments · program years 2019–2025
  1. Neurostar TMS Therapy System $493 6 payments
  2. VRAYLAR Neuroscience $205 27 payments
  3. COBENFY $108 11 payments
  4. CAPLYTA Psychiatry $65 2 payments
  5. VRAYLAR Neuroscience $57 3 payments
  6. REXULTI $51 3 payments
  7. CAPLYTA Psychiatry $50 2 payments
  8. ABILIFY ASIMTUFII $50 2 payments
  9. UZEDY $40 2 payments
  10. QUVIVIQ $35 2 payments
  11. Other $300 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

13,813

Median for Psychiatry: 574

Drug cost

$2,799,363

Median for Psychiatry: $27,624

Branded share of claims

20.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 60 $519,680
Austedo Xr Deutetrabenazine Brand 87 $432,516
Invega Sustenna Paliperidone Palmitate Brand 117 $396,751
Ingrezza Valbenazine Tosylate Brand 32 $265,040
Aristada Aripiprazole Lauroxil Brand 41 $149,905
Caplyta Lumateperone Tosylate Brand 58 $93,617
Lybalvi Olanzapine/Samidorphan Malate Brand 54 $84,976
Risperdal Consta Risperidone Microspheres Brand 36 $83,472
Vraylar Cariprazine Hcl Brand 51 $66,244
Fanapt Iloperidone Brand 27 $59,339

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$64,928

Medicare's payments for the services billed

Medicare patients

245

Average age 69

Services billed

845

143 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 65%
High blood pressure 61%
Arthritis 40%
Chronic kidney disease 25%
Diabetes 23%
Ischemic heart disease 23%
COPD 17%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $18
$18 58 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $18
$18 — —
VIVITROL
  • Alkermes, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record